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Abstract 
Background: Sustained drug delivery is a large unmet clinical need in glaucoma. Here, we incorporated a Myocar‑
din‑Related Transcription Factor/Serum Response Factor inhibitor, CCG‑222740, into slow release large unilamellar 
vesicles derived from the liposomes DOTMA (1,2‑di‑O‑octadecenyl‑3‑trimethylammonium propane) and DOPC 
(1,2‑dioleoyl‑sn‑glycero‑3‑phosphocholine), and tested their effects in vitro and in vivo.
Results: The vesicles were spherical particles of around 130 nm and were strongly cationic. A large amount of 
inhibitor could be incorporated into the vesicles. We showed that the nanocarrier CCG‑222740 formulation gradually 
released the inhibitor over 14 days using high performance liquid chromatography. Nanocarrier CCG‑222740 signifi‑
cantly decreased ACTA2 gene expression and was not cytotoxic in human conjunctival fibroblasts. In vivo, nanocarrier 
CCG‑222740 doubled the bleb survival from 11.0 ± 0.6 days to 22.0 ± 1.3 days (p = 0.001), decreased conjunctival scar‑
ring and did not have any local or systemic adverse effects in a rabbit model of glaucoma filtration surgery.
Conclusions: Our study demonstrates proof‑of‑concept that a nanocarrier‑based formulation efficiently achieves a 
sustained release of a Myocardin‑Related Transcription Factor/Serum Response Factor inhibitor and prevents conjunc‑
tival fibrosis in an established rabbit model of glaucoma filtration surgery.
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Background
Drug delivery and duration of action remain major hur-
dles in the development of new anti-scarring therapies 
in the eye. Potential slow-release formulations, such as 
hydrogels [1], ocular tablets [2, 3], microspheres [4], 
microfilms [5], or ocular implants [6], are being devel-
oped for sustained drug delivery to the conjunctiva. Glau-
coma is the leading cause of irreversible blindness in the 
world, currently affecting over 64 million people world-
wide and its prevalence is estimated to rise to 76 million 
by 2020 and 112 million by 2040 [7]. Glaucoma filtration 
surgery (GFS) is the mainstay of surgical treatment but is 
often complicated by post-surgical fibrosis, which is the 
principal cause of blockage of aqueous flow at the drain-
age site leading to failure of surgery [8].
Serum response factor (SRF) is a ubiquitous tran-
scription factor that controls growth factor regulated 
immediate early genes like c-fos and actin, as well as 
muscle-specific genes [9–11]. SRF is also a master regu-
lator of cytoskeletal gene expression [12, 13], including 
many genes involved in fibrosis [14–17]. The Myocardin-
related Transcription Factor family, MRTF-A and MRTF-
B, is one of the principal families of signal-regulated SRF 
cofactors. They are controlled by cytoskeletal dynamics, 
responding to variations in the cellular concentration of 
G-actin to which they bind through N-terminal RPEL 
motifs [18, 19].
We have previously shown that repeated injections 
of an MRTF/SRF inhibitor, CCG-222740, effectively 
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prevented scar tissue formation in a rabbit model of 
experimental GFS [20]. Our hypothesis is that a nano-
carrier-based formulation of CCG-222740 will achieve 
a sustained release of the drug from a single adminis-
tration and have similar efficacy compared to repeated 
injections. In this study, we evaluated in vitro the efficacy 
and safety of a novel sustained release nanocarrier-based 
formulation of CCG-222740 in human conjunctival 
fibroblasts. We also tested the effects of the nanocarrier 
CCG-222740 formulation on bleb survival and conjunc-
tival fibrosis using a rabbit in vivo model of experimental 
GFS.
Methods
Materials
DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium 
propane) and DOPC (1,2-dioleoyl-sn-glycero-3-phos-
phocholine) were purchased from Avanti Polar Lipids 
(Alabama, USA). CCG-222740 inhibitor was synthesised 
and characterised in the Vahlteich Medicinal Chemis-
try Core at the University of Michigan. The inhibitor 
was > 95% pure by high performance liquid chromatogra-
phy (HPLC). HPLC grade (> 99% purity) solvents, includ-
ing acetronitrile, trifluoroacetic acid, chloroform and 
methanol, were bought from Sigma, UK. All glassware 
was sterilised by autoclaving and procedures were per-
formed under aseptic conditions in a cell culture hood.
Preparation of large unilamellar vesicles
Nanocarrier formulation of CCG-222740 was pre-
pared by the thin film hydration technique as previously 
described [21]. Equal amounts (0.66  mg) of DOTMA 
(lipid concentration dissolved in chloroform = 25  mg/
ml) and DOPC (lipid concentration dissolved in chloro-
form = 25 mg/ml) were added to CCG-222740 (0.68 mg, 
CCG-222740 concentration dissolved in metha-
nol = 2  mg/ml). Solvents were removed from the round 
bottom flask (VWR, UK) using a rotary evaporator 
(Model R-100, BUCHI, UK) and a thin dry drug-loaded 
lipid film was obtained. Following the initial evapora-
tion of the organic solvents and the thin film formation 
using the rotary evaporator, we continued the evapora-
tion procedure at ‘full power’ for at least 30 more minutes 
to make sure that no traces of solvents were left. 1 ml of 
MilliQ-filtered water was added to hydrate the film. The 
mixture was sonicated for 5–10  min to form large uni-
lamellar vesicles (LUVs) using a sonicator (Grant Instru-
ments Ltd, UK). After completion of the sonication step, 
the resulting formulation was extruded through a 0.22 
μm polycarbonate filter membrane (Merck Millipore, 
USA).
Cell culture
Human conjunctival fibroblasts were grown from con-
junctival tissues collected from glaucoma patients dur-
ing glaucoma filtration surgery. Informed consent was 
obtained from all subjects. The fibroblasts were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen, UK) with 10% fetal calf bovine serum (FBS), 
100 U/ml penicillin, 100  mg/ml streptomycin, and 
2  nM  l-glutamine, in tissue culture incubators with 5% 
 CO2 and 95% humidity. Fibroblasts between passages 
2–8 were used in all experiments. All experimental pro-
tocols were approved by the London-Dulwich Research 
Ethics Committee (REC 10/H0808/127) and the institu-
tional approval committee at the University College Lon-
don Institute of Ophthalmology.
Size and zeta potential
Nanocarrier size and zeta potential were determined 
by dynamic light scattering (DLS) and laser Doppler 
anemometry, respectively, using a Nano ZS Zetasizer 
(Malvern Instruments, Malvern, UK) with the following 
specifications: automatic sampling time of 10 measure-
ments/sample, refractive index 1.330, dielectric constant 
78.5, viscosity 0.887 cP, and temperature of 25  °C. Zeta 
potential settings were calibrated against the standard 
(− 68 ± 6.8  mV). Triplicate measurements were per-
formed for each sample and the results were analysed 
using the software provided by the manufacturer (DTS 
version 5.03).
Transmission electron microscopy (TEM)
The nanocarrier CCG-222740 formulation was applied 
onto a 300-mesh copper grid coated with a Formvar/
carbon support (Agar Scientific, Stansted, UK) and pro-
cessed as previously described [22]. The sample was neg-
atively stained with 1% phosphotungstic acid for 2–3  s, 
before blotting with filter paper and air-drying. Imaging 
was performed with a Philips CM120 BioTwin Transmis-
sion Electron Microscope and operated at an accelerating 
voltage of 120 kV. Images were captured using an AMT 
5MP digital TEM camera (Deben UK Limited, UK).
Drug release studies
Drug release studies were performed using an acrylic flow 
rig model consisting of a 200-μl cell to mimic the surgical 
bleb area in GFS [2]. The rig had both input and output 
tubes. The input tube was connected to a high precision 
multi-channel dispenser (ISMATEC pump, Switzerland) 
to pump MilliQ-filtered water at a flow rate of 2 μl/min 
to simulate the typical flow of aqueous humour in the 
eye. The experiments were performed at 37 °C to mimic 
the temperature of the subconjunctival space. The output 
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tube was used for collection of samples at various time 
points. Aliquots from the release medium were collected 
in amber colour HPLC vials (2  ml, Agilent, UK) and 
stored at 4 °C until they were measured. The drug release 
experiments were performed in triplicates per condition 
and each experiment was repeated three times.
High performance liquid chromatography (HPLC)
The drug concentrations were measured using the Agi-
lent Technologies 1260 Infinity HPLC system (Agilent, 
UK) and detected by UV absorbance. A reverse phase 
Agilent Eclipse XDB-C18 column (5 μm, 4.6 × 150 mm) 
was used at 1  ml/min flow rate, injection volume of 10 
μl, and UV detection wavelength of 254 nm. The mobile 
phase was acetonitrile: 0.1% trifluoroacetic acid at 65:35 
proportions (volume/volume percentages). The drug 
estimation from the release medium was performed 
directly from the collected samples. The HPLC system 
was calibrated  (R2 = 0.998) using known concentrations 
of CCG-222740 (2.5, 5, 10, 20, 30, 40, 50 μg/ml) by dilut-
ing CCG-222740 in methanol.
Real‑time quantitative PCR
Human conjunctival fibroblasts were plated at 1 × 105 
cells/well in 6-well plates (Falcon, Fisher Scientific). The 
next day, the fibroblasts were treated with 1.25, 2.5, 5 or 
10 μM of nanocarrier CCG-222740 or empty liposomes 
in DMEM + 10% FCS for 24 h. The fibroblasts were then 
lysed for RNA extraction using the RNeasy mini kit 
(Qiagen, UK) according to the manufacturer’s instruc-
tions. RT-qPCR reactions were performed using a Sen-
siFAST™ SYBR Hi-ROX One-Step master mix (Bioline, 
UK) on a QuantStudio5 Real-Time PCR system (Ther-
moFisher, UK). The qRT-PCR assay conditions were: 
stage 1, 45 °C for 20 min; stage 2, 95 °C for 3 min; stage 3, 
95 °C for 10 s, then 60 °C for 25 min; repeated 40 times. 
The human Taqman gene expression assays were ACTA2 
(Hs00426835_g1) and GAPDH (Hs02786624_g1) (Ther-
moFisher Scientific, UK). All mRNA values were normal-
ised relative to that of GAPDH and triplicate experiments 
were performed for each condition.
Cell proliferation assay
Human conjunctival fibroblasts were plated at 6.25 × 103 
cells/well in 96-well plates (Falcon, Fisher Scientific, UK), 
and treated with 1.25, 2.5, 5 or 10 μM of nanocarrier 
CCG-222740 or empty liposomes for 24 h. The medium 
was replaced by 100 μl fresh growth medium per well and 
20 μl of the Cell Titer 96 Aqueous one solution (Promega, 
UK) were added to each well. The cells were incubated 
for 2  h and absorbance at 540  nm was measured using 
a FLUOstar Omega (BMG LABTECH, UK). Cell viability 
for each formulation was expressed as a percentage of the 
viability of control cells. Each experiment was carried out 
with six independent replicates for each condition.
Rabbit glaucoma filtration surgery (GFS) model of scar 
tissue formation
All animal procedures were performed in accordance 
with the Association of Research in Vision and Ophthal-
mology (ARVO) Statement for the Use of Animals in 
Ophthalmic and Vision Research, and all animal experi-
mental protocols were approved by the Home Office 
UK (PPL 70/8074). Eighteen female New Zealand white 
rabbits (1.5–2  kg, 10–12  weeks, Envigo, UK) under-
went experimental GFS to the left eye under general 
anaesthesia [23, 24]. A superonasal fornix-based con-
junctival flap was raised behind the limbus and a micro-
vitreoretinal blade (20 gauge, 0.90  mm, Surgistar USA) 
was used to make a partial thickness scleral tunnel to 
the corneal stroma. A 22 gauge, 25 mm intravenous can-
nula was passed through the tunnel and the needle was 
removed once it was visible in the cornea. The cannula 
was advanced into the mid-pupillary area, trimmed at its 
scleral edge and fixed to the scleral surface using a 10-0 
nylon suture (Alcon, USA). The conjunctival incision was 
closed using two interrupted 10-0 nylon sutures. In a ran-
domised, prospective, single-masked observer study, the 
rabbits received either intraoperative 0.2 mg/ml mitomy-
cin-C (MMC) [N = 6], or postoperative subconjunctival 
injections of 68 μg in 100 μl of nanocarrier CCG-222740 
[N = 6] or empty liposomes [N = 6].
Post‑operative clinical examination
The animals were evaluated every 3  days by a single-
masked blinded researcher. Bleb width and length were 
measured using calipers and intraocular pressures were 
measured using a tonovet (Icare, UK). The primary effi-
cacy end-point was bleb survival as this is indicative of 
the long-term patency of the filtration pathway created 
during surgery. Bleb failure was defined as the appear-
ance of a flat, scarred and vascularised bleb associated 
with a deep anterior chamber.
Histologic analysis
The animals were sacrificed on day 30 and both eyes 
were enucleated. The eyes were fixed in formalin, embed-
ded in paraffin, and sequential 4 μm tissue sections were 
cut. The sections were stained with hematoxylin and 
eosin (for cellularity and inflammatory cells), Gomori’s 
trichrome (for collagen), picrosirius red (for degree of 
fibrosis), and alpha-smooth muscle actin (αSMA) using 
a primary monoclonal mouse anti-human αSMA anti-
body (Clone 1A4; Dako, High Wycombe, UK) and a bioti-
nylated secondary antibody (rabbit anti-mouse; Dako). 
All the left operated eyes were compared to the right 
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non-operated eyes that were used as controls for normal 
conjunctival tissue.
Toxicity and pharmacokinetics
All animals were evaluated for signs of local or sys-
temic toxicity during the study. Conjunctival vascularity 
was graded as 0, avascular; 1, normal; 2, hyperaemic; 3, 
very hyperaemic. Anterior chamber inflammation was 
graded as 0, quiet; 1, cells; 2, fibrin; 3, hypopyon. At day 
30, 100 µl of aqueous and 1 ml of vitreous were sampled 
from the rabbit eyes receiving nanocarrier CCG-222740 
or empty liposomes. The levels of CCG-222740 were 
measured in the aqueous and vitreous samples using the 
HPLC method as described above.
Statistical analysis
All graphs display mean and standard error of the 
mean (SEM). Statistical analysis was performed using 
the Student’s t test to calculate statistically significant 
differences and p values. Survival analysis for bleb 
was performed using the Kaplan–Meier log rank test. 
Statistically significant differences were expressed as 
*p < 0.05; **p < 0.01; ***p < 0.001.
Results
Development and biophysical characterisation 
of nanocarrier CCG‑222740 formulation
Figure 1a shows the molecular structure of the MRTF/
SRF inhibitor CCG-222740 (MW 444.9  g/mol). The 
nanocarrier CCG-222740 formulation was spherical 
particles as shown by negative-staining transmission 
electron microscopy (Fig.  1b). Nanocarrier CCG-
222740 had a mean size of 137.0 ± 7.1  nm compared 
to 84.8 ± 2.8  nm for empty liposomes (Fig.  1c). Both 
nanocarrier CCG-222740 and empty liposomes were 
strongly cationic with a mean charge of +63.0 ± 1.5 mV 
and +75.2 ± 0.6  mV, respectively (Fig.  1d). Nanocar-
rier CCG-222740 and empty liposomes had relatively 
low polydispersity indices (PDI) of 0.39 ± 0.02 and 
0.39 ± 0.01, respectively, indicating a narrow particle 
size distribution (Fig. 1e).
Fig. 1 Molecular structure of an MRTF/SRF inhibitor a CCG‑222740. b Negative staining transmission electron microscopy of the nanocarrier 
CCG‑222740 formulation. c Size; d Zeta potential; and e Polydispersity index of the nanocarrier CCG‑222740 formulation and empty liposomes were 
measured using a Nano ZS Zetasizer. Results represent mean ± SEM for triplicate measurements
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Effect of nanocarrier CCG‑222740 on ACTA2 gene 
expression and cell viability in human conjunctival 
fibroblasts
ACTA2, coding for alpha-smooth muscle actin, is a direct 
target gene of the MRTF/SRF pathway that is classically 
linked to fibrosis [12]. Our results show that nanocar-
rier CCG-222740 formulation significantly decreased 
ACTA2 gene expression in human conjunctival fibro-
blasts by 63.0% (p = 0.0468), 61.0% (p = 0.0257) and 
71.2% (p = 0.0327) at 2.5, 5 and 10 μM concentrations, 
respectively, compared to empty liposomes (Fig.  2a). 
There was a vehicle effect with empty liposomes also 
causing a decrease in the ACTA2 gene expression com-
pared to untreated cells. This is a non-specific effect 
which has been observed by others in siRNA [25, 26] or 
drug-loaded liposomes [27]. Most likely this effect would 
not be seen if repeat transfections were performed. 
There were no significant differences in the ACTA2 gene 
between empty liposomes and 1.25 μM nanocarrier 
CCG-222740 (Fig. 2a).
As 24 h of treatment were sufficient to determine a sig-
nificant decrease in ACTA2 gene expression in  vitro in 
human conjunctival fibroblasts, we have thus measured 
cell viability 24  h post-transfection similar to previous 
studies [20]. We next tested the toxicity of nanocarrier 
CCG-222740 on human conjunctival fibroblasts. Differ-
ent concentrations of nanocarrier CCG-222740 did not 
have any significant effect on cell viability compared to 
empty liposomes and untreated cells (Fig. 2b).
Nanocarrier CCG‑222740 achieves a sustained drug release 
as measured by high performance liquid chromatography
We used a customised 200-μl cell with an open flow sys-
tem for our drug release experiments as it mimics the 
conditions of the subconjunctival space, namely flow of 
aqueous humour and temperature, and allows collec-
tion of the released media at different time points [2]. We 
first calculated a calibration curve (y = 26.399x − 34.826; 
 R2 = 0.99788) for CCG-222740 and used it to measure the 
drug concentrations in the released media using HPLC. 
The drug release concentration peaked at 13.4 ± 6.4 μg/
ml at 0.5  day and stabilised at approximately 2 μg/ml 
from day 1 thereafter (Fig. 3a).
We used a flow rate of 2 μl per minute to simulate the 
typical flow of aqueous humour in the eye, so that 2.88 ml 
were collected over 24  h. The mean amount of drug 
released was 19.3 μg (13.4 μg/ml × 1.44 ml) at 0.5 day and 
approximately 5.8 μg daily (2 μg/ml × 2.88 ml) from day 
1 thereafter. Out of the total of 68 μg of drug used, the 
nanocarrier CCG-222740 formulation led to a sustained 
cumulative drug release of 28.4 ± 13.6%, 32.1 ± 13.5%, 
45.1 ± 13.3%, 63.7 ± 13.5%, 79.8 ± 12.6%, 91.1 ± 8.8% and 
93.1 ± 6.9% at 0.5, 1, 3, 6, 9, 12 and 14 days, respectively 
(Fig. 3b).
Fig. 2 Human conjunctival fibroblasts were treated with different 
concentrations of nanocarrier CCG‑222740 or empty liposomes 
for 24 h. a ACTA2 gene expression was measured by real‑time 
quantitative PCR. Results represent mean ± SEM for triplicate 
experiments. *P < 0.05. Comparisons shown are between cells treated 
with different concentrations of nanocarrier CCG‑222740 or empty 
liposomes. b Effect on cell viability was measured using CellTiter 96 
Aqueous one solution assay. Results represent mean ± SEM for six 
replicates per condition. The comparisons of cell viabilities shown are 
between cells treated with different concentrations of nanocarrier 
CCG‑222740 or empty liposomes
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In vivo administration of nanocarrier CCG‑222740 
increases the long‑term success of surgery in a rabbit 
model of GFS
We used an established and clinically validated rabbit 
model of experimental GFS to investigate the effects 
of nanocarrier CCG-222740 on wound healing in the 
conjunctiva [20, 23, 24]. Subconjunctival scarring after 
glaucoma filtration surgery is one of the most aggres-
sive models of scar tissue formation, and failure of sur-
gery is due to excessive scarring. A bleb arises when 
a filtration cannula is inserted during the surgery and 
drains aqueous fluid from the anterior chamber of the 
eye to under the conjunctiva. The primary efficacy end-
point of the study was bleb survival as this is indica-
tive of the long-term opening of the filtration pathway 
created during the surgery. Bleb survival doubled from 
11.0 ± 0.6  days for empty liposomes to 22.0 ± 1.3  days 
for nanocarrier CCG-222740 (p = 0.001) (Fig.  4a and 
b). We also compared the bleb survival between the 
standard dose of mitomycin-C (MMC, 0.2 mg/ml) and 
nanocarrier CCG-222740 (inhibitor concentration, 
0.68  mg/ml). The surgical outcome for nanocarrier 
CCG-222740 was similar to that of MMC, which had a 
bleb survival of 22.5 ± 1.3 days.
Nanocarrier CCG‑222740 decreases conjunctival scarring 
and does not cause any local or systemic side effects
We evaluated the histologic differences in the conjunc-
tiva after local delivery of nanocarrier CCG-222740. 
Our results show that nanocarrier CCG-222740 signifi-
cantly decreased the scar tissue formation in the rab-
bit conjunctiva compared to empty liposomes (Fig.  5a). 
Total cellularity was also significantly increased in the 
empty liposomes group compared to the nanocarrier 
CCG-222740 group (Fig.  5b). In addition, nanocarrier 
CCG-222740 significantly decreased the expression of 
alpha-smooth muscle actin (αSMA) by cells, suggesting 
the presence of fewer myofibroblasts (Fig. 5c). The pres-
ence of newly laid collagen was also present to a greater 
degree in the vehicle control group compared to the 
nanocarrier CCG-222740 group (Fig. 5d).
Local tissue reaction to treatment was further assessed 
by conjunctival vascularity. MMC treatment led to thin 
avascular blebs with a vascularity grade of 0.7 ± 0.2 
(SEM) at day 30 compared to 1.3 ± 0.1 for empty 
liposomes (p = 0.022) (Fig.  6a). At day 30, there were 
no statistically significant differences in the vascular-
ity grade between the nanocarrier CCG-222740-treated 
group (1.5 ± 0.1) and the empty liposomes-treated group 
(1.3 ± 0.1, p = 0.121). There were also no signs of corneal 
or conjunctival toxicities or anterior chamber inflamma-
tion (inflammation grade = 0) noted after local delivery of 
the nanocarrier CCG-222740 formulation (Fig. 6b).
In addition, the rabbits were carefully monitored 
throughout the study and none of them showed any signs 
of systemic toxicity after local delivery of the nanocarrier 
CCG-222740 formulation to the conjunctiva. We also 
tested the concentrations of CCG-222740 at day 30 in the 
aqueous and vitreous of the rabbits using HPLC. Levels 
of CCG-222740 were very low or undetectable in all the 
aqueous and vitreous samples.
Discussion
Therapeutic nanomedicine is an area of great research 
interest in glaucoma [28] and our study provides proof-
of-concept that small molecule inhibitors can be for-
mulated into nanocarrier liposomal formulations for 
sustained drug delivery to the conjunctiva. The sub-
conjunctival space is an area with constant flow of 
aqueous fluid and drugs are rapidly cleared from the 
Fig. 3 Drug release studies of nanocarrier CCG‑222740. a 
Concentration curve of nanocarrier CCG‑222740 and empty 
liposomes over 14 days. b Cumulative drug release of nanocarrier 
CCG‑222740 and empty liposomes over 14 days. Results represent 
mean ± SEM for three independent experiments
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subconjunctival space after GFS. Development of sus-
tained release drug formulations with better pharmacoki-
netics and longer duration of action is thus crucial for 
successful drug delivery to the conjunctiva after GFS.
Large unilamellar vesicles (LUVs) and multilamellar 
vesicles (MLVs) can significantly increase the bioavail-
ability and efficacy of drugs in the eye. MLVs containing 
acetazolamide were more efficient than an acetazolamide 
solution in lowering the intraocular pressure (IOP) [29]. 
LUVs containing latanaprost also maintained the IOP-
lowering effect of latanaprost for up to 50 days in a rab-
bit model [30]. In addition, liposomal ganciclovir had 
an ocular bioavailability that was 1.7-fold higher than 
that of a ganciclovir solution [31]. Charge also plays an 
important role in sustained drug delivery and positively 
charged or neutral liposomes tend to have a more pro-
longed effect than negatively charged ones [29]. In our 
study, the liposomes were strongly cationic and gradually 
released the MRTF/SRF inhibitor over a sustained period 
of 14  days. Several administrations of the nanocarrier 
CCG-222740 formulation, for example every 2  weeks, 
would achieve a more prolonged release of the drug to 
prevent conjunctival fibrosis in the post-operative period 
after GFS.
Different liposomes and drug: liposome ratios are cur-
rently being tested for different types of drugs. In this 
study, we used inhibitor: DOTMA: DOPC in a 1:1:1 
molar ratio and we incorporated a large amount of inhib-
itor in the liposomes. Latanaprost: di-palmitoyl-phos-
phatidyl-choline formulations at a molar ratio of 1:10 also 
had good physical stability and release, and demonstrated 
sustained release of latanoprost in  vitro and in a rabbit 
model [30, 32]. MLVs composed of phosphatidylcholine: 
cholesterol: stearylamine in a 7:4:1 ratio also effectively 
packaged acetazolamide, which was adjusted at a concen-
tration of 1%, and demonstrated maximal lowering effect 
of the intraocular pressure [29].
Using a high-throughput screen with an MRTF/SRF 
reporter gene that selectively responds to RhoA-induced 
gene transcription [33], CCG-1423 was identified as a 
first generation inhibitor of RhoA-stimulated MRTF/SRF 
gene transcription [34]. A second generation inhibitor, 
CCG-203971, was optimised that is of equal efficacy but 
less cytotoxic than CCG-1423 [35, 36]. Another second 
generation MRTF/SRF pathway inhibitor, CCG-222740, 
has also been developed and is more potent and meta-
bolically stable than CCG-203971 [20, 37]. However, the 
molecular target of the MRTF/SRF inhibitors has not yet 
definitively been established. A previous study on the 
Fig. 4 Effect of nanocarrier CCG‑222740 on a rabbit model of glaucoma filtration surgery. a Morphology of blebs after surgery and treatment with 
nanocarrier CCG‑222740, empty liposomes or mitomycin‑C (MMC) at day 14. Arrows indicate bleb edges. b Kaplan–Meier graph comparing the 
bleb survival between nanocarrier CCG‑222740 [N = 6], empty liposomes [N = 6] and MMC [N = 6]
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MRTF/SRF pathway inhibitor CCG-1423 reported that it 
increases nuclear G-actin and decreases MRTF-A in the 
nucleus through inhibition of MICAL-2, a member of the 
MICAL family of actin-binding mono-oxygenases [38]. 
Another study also reported that CCG-1423 acts directly 
on MRTF and other RPEL-family of proteins to prevent 
the nuclear import of MRTF-A [39].
Mitomycin-C is a toxic antimetabolite and exerts its 
anti-scarring effects by arresting the cell cycle and caus-
ing widespread apoptosis of fibroblasts in the conjunctiva 
[40]. Vision-threatening side effects have been associated 
with the use of mitomycin-C, namely hypotonous macu-
lopathy [41], severe infection [42], and corneal melting 
and perforation [43]. Our previous study showed that 
repeated subconjunctival injections of CCG-222740 did 
not cause any detectable local toxicity with an intact and 
healthy-looking conjunctival epithelium that was similar 
to the non-operated eyes, and with normal Ki67 posi-
tive cells (marker of cell proliferation) in the conjunctival 
epithelium [20]. Similarly, our current study showed that 
the nanocarrier liposomal formulation of CCG-222740 
was not associated with any signs of corneal or conjunc-
tival toxicities or anterior chamber inflammation. MMC 
treatment led to thin avascular blebs but there were no 
abnormalities in conjunctival vascularity noted in the 
nanocarrier CCG-222740-treated group. Other studies 
have also reported that nanosized liposomal formulations 
of drugs do not lead to significant toxicity and inflamma-
tion in the eye [21, 30].
Conclusion
Our study provides proof-of-concept that a nanocar-
rier-based formulation achieved a sustained release 
of an MRTF/SRF inhibitor over time and prevented 
Fig. 5 Histology of rabbit conjunctival tissues. The left operated eyes were compared to the right non‑operated eyes that were used as controls for 
normal conjunctival tissue. Scale bar = 100 μm; c, conjunctiva, b, subconjunctival space, s, sclera. a Picrosirius red; b H&E; c Alpha‑smooth muscle 
actin (αSMA); d Gomori’s trichrome stain
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conjunctival fibrosis in a rabbit model of experimental 
GFS. The nanocarrier formulation was also safe to use 
and did not cause any ocular or systemic adverse effects.
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